Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ARCT
- Price
- 7.40
- Stock movement down
- -0.30 (-3.76%)
- Company name
- Arcturus Therapeutics Holdings Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 217.94M
- Ent value
- 95.36M
- Price/Sales
- 2.37
- Price/Book
- 0.97
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 6.84%
- 1 year return (CAGR)
- -55.72%
- 3 year return (CAGR)
- -25.66%
- 5 year return (CAGR)
- -36.36%
- 10 year return (CAGR)
- -14.65%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ARCT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.37 |
| Price to Book | 0.97 |
| EV to Sales | 1.04 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 28.41M |
| EPS (TTM) | -2.45 |
| FCF per share (TTM) | -2.16 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 92.04M |
| Gross profit (TTM) | 88.70M |
| Operating income (TTM) | -78.35M |
| Net income (TTM) | -66.71M |
| EPS (TTM) | -2.45 |
| EPS (1y forward) | -2.66 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 96.37% |
| Operating margin (TTM) | -85.12% |
| Profit margin (TTM) | -72.48% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 180.36M |
| Net receivables | 7.95M |
| Total current assets | 249.20M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 43.23M |
| Total assets | 282.34M |
| Accounts payable | 5.49M |
| Short/Current long term debt | 21.86M |
| Total current liabilities | 31.70M |
| Total liabilities | 57.78M |
| Shareholder's equity | 224.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -58.33M |
| Capital expenditures (TTM) | 320.45K |
| Free cash flow (TTM) | -58.65M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -29.71% |
| Return on Assets | -23.63% |
| Return on Invested Capital | -29.71% |
| Cash Return on Invested Capital | -26.12% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.79 |
| Daily high | 7.93 |
| Daily low | 7.54 |
| Daily Volume | 409K |
| All-time high | 178.57 |
| 1y analyst estimate | 33.56 |
| Beta | 2.43 |
| EPS (TTM) | -2.45 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 2 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ARCT | S&P500 | |
| Current price drop from All-time high | -95.86% | -1.82% |
| Highest price drop | -97.70% | -56.47% |
| Date of highest drop | 28 Dec 2018 | 9 Mar 2009 |
| Avg drop from high | -79.24% | -10.84% |
| Avg time to new high | 153 days | 12 days |
| Max time to new high | 3112 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
217.94M
Marketcap category
Small-cap
Description
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Employees
174
Website
Investor relations
SEC filings
CEO
Joseph E. Payne
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page